Table 2 Demographic and clinical features of RRMS patients and healthy donors.

From: Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients

 

HD

RRMS

Natalizumab infusion number

0

3

6

12

15

18

24

Number of samples

10

18

11

14

26

10

8

29

F/M

5/5

6/12

4/7

8/6

13/13

5/5

4/4

16/13

Median age in years [IQR]

30 [27.0–34.5]

38 [32–43]

43 [40–42]

39 [38–43]

38 [32–43]

39 [29–44]

40 [36–43]

38 [33–43]

Median years of disease [IQR]

—

8 [6–10]

10 [9–12]

10 [7–13]

8 [6–10]

10 [7–17]

9 [6–14]

8 [6–11]

Median EDSS [IQR]

—

2 [1–2]

1 [1.8–2]

2 [2–3]

2 [1–2]

1.5 [1–2]

2 [1–2]

2 [1–3]

No therapy* (/N)

—

4/18

2/11

2/14

6/26

2/10

2/8

8/29

Interferon β* (/N)

—

12/18

7/11

11/14

17/26

8/10

6/8

18/29

Mitoxantrone and Interferon β* (/N)

—

1/18

1/11

1/14

1/26

0/10

0/8

1/29

Glatimer acetate* (/N)

—

1/18

1/11

0/14

2/26

0/10

0/0

2/29

  1. HD: healthy donors; RRMS: relapsing-remitting multiple sclerosis; F: female; M: male; IQR: interquartile range; N: number of samples; EDSS: Expanded Disability Status Scale, with values ranging from 0 (normal neurological examination) to 10 (bedridden patient)39 *therapy before starting natalizumab.
Back to article page